JP2008501649A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501649A5
JP2008501649A5 JP2007513783A JP2007513783A JP2008501649A5 JP 2008501649 A5 JP2008501649 A5 JP 2008501649A5 JP 2007513783 A JP2007513783 A JP 2007513783A JP 2007513783 A JP2007513783 A JP 2007513783A JP 2008501649 A5 JP2008501649 A5 JP 2008501649A5
Authority
JP
Japan
Prior art keywords
group
compound
formula
lower alkyl
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007513783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501649A (ja
JP4594386B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/005594 external-priority patent/WO2005117865A1/en
Publication of JP2008501649A publication Critical patent/JP2008501649A/ja
Publication of JP2008501649A5 publication Critical patent/JP2008501649A5/ja
Application granted granted Critical
Publication of JP4594386B2 publication Critical patent/JP4594386B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007513783A 2004-06-02 2005-05-24 ヒスタミン3受容体のリガンドとして有用なナフタレン誘導体 Expired - Fee Related JP4594386B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102460 2004-06-02
PCT/EP2005/005594 WO2005117865A1 (en) 2004-06-02 2005-05-24 Naphthaline derivatives useful as histamine-3-receptor ligands

Publications (3)

Publication Number Publication Date
JP2008501649A JP2008501649A (ja) 2008-01-24
JP2008501649A5 true JP2008501649A5 (enExample) 2010-09-24
JP4594386B2 JP4594386B2 (ja) 2010-12-08

Family

ID=34982058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513783A Expired - Fee Related JP4594386B2 (ja) 2004-06-02 2005-05-24 ヒスタミン3受容体のリガンドとして有用なナフタレン誘導体

Country Status (24)

Country Link
US (2) US7259158B2 (enExample)
EP (1) EP1755593B1 (enExample)
JP (1) JP4594386B2 (enExample)
KR (1) KR100854212B1 (enExample)
CN (1) CN1960727B (enExample)
AR (1) AR049433A1 (enExample)
AT (1) ATE383857T1 (enExample)
AU (1) AU2005249196B2 (enExample)
BR (1) BRPI0511778A (enExample)
CA (1) CA2566526C (enExample)
DE (1) DE602005004404T2 (enExample)
DK (1) DK1755593T3 (enExample)
ES (1) ES2299074T3 (enExample)
IL (1) IL179370A (enExample)
MX (1) MXPA06014017A (enExample)
MY (1) MY139704A (enExample)
NO (1) NO20065733L (enExample)
NZ (1) NZ550764A (enExample)
PL (1) PL1755593T3 (enExample)
PT (1) PT1755593E (enExample)
RU (1) RU2387638C2 (enExample)
TW (1) TWI299992B (enExample)
WO (1) WO2005117865A1 (enExample)
ZA (1) ZA200609678B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097149A1 (ja) * 2006-02-20 2007-08-30 Konica Minolta Holdings, Inc. 有機エレクトロルミネッセンス素子、白色発光素子、表示装置、及び照明装置
ES2627221T3 (es) 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
MX2009011787A (es) 2007-05-03 2009-11-13 Cephalon Inc Procesos para preparar (r)-2-metilpirrolidina y (s)-2-metilpirrolidina y sales de tartrato de las mismas.
EP2231600B1 (en) 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2231666B1 (en) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
WO2009132136A1 (en) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
AR081034A1 (es) 2010-05-11 2012-05-30 Sanofi Aventis Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central
AR081908A1 (es) 2010-05-11 2012-10-31 Sanofi Aventis N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas
EP2569294B1 (en) 2010-05-11 2015-03-11 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
JP5766278B2 (ja) 2010-05-11 2015-08-19 サノフイ 置換されたn−アルキルおよびn−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用
WO2011143161A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
KR101408699B1 (ko) 2012-02-29 2014-06-19 중앙대학교 산학협력단 지르코늄 선택적 형광 프루브
BR112015001613B1 (pt) * 2012-07-27 2021-02-23 Biogen Ma Inc compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx, seus usos e composição farmacêutica
EP2877185B1 (en) 2012-07-27 2018-05-23 Biogen MA Inc. 2-(1-(1-(6-((cyclohexyl)oxy)-5-(trifluoromethyl)naphthalen-2-yl)ethyl)piperidin-3-yl)acetic acid derivatives as autotaxin (atx) modulators for the treatment of inflammations and autoimmune disorders
CA2878217C (en) * 2012-08-23 2016-05-17 Suven Life Sciences Limited Acrylamide compounds as histamine h3 receptor ligands
CN117229207B (zh) * 2023-09-01 2024-09-03 浙江工业大学 一种苯基萘类化合物及其制备与应用
CN121494783B (zh) * 2026-01-13 2026-05-26 安徽农业大学 四氢异喹啉酰胺衍生物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19621483A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CN1159292C (zh) * 1996-05-31 2004-07-28 法玛西雅厄普约翰美国公司 用作选择性多巴胺d3配体的芳基取代的环胺类化合物
JP2004532834A (ja) * 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンh3受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
CA2765093A1 (en) * 2002-11-12 2004-05-27 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
BRPI0518222A (pt) * 2004-10-19 2008-11-04 Hoffmann La Roche composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos

Similar Documents

Publication Publication Date Title
JP2007500753A5 (enExample)
WO2008006043A3 (en) 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
JP2005514410A5 (enExample)
JP2005523310A5 (enExample)
JP2009541415A5 (enExample)
JP2009541403A5 (enExample)
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
EP2085388A4 (en) NEW 1,2-DIHYDROCHINOLINE DERIVATIVE WITH SUBSTITUTED PHENYLAMINOENE ALKYL GROUP AND PHENYL GROUP INTRODUCED BY AN ESTER AS SUBSTITUENTS
JP2010520851A5 (enExample)
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
JP2004535380A5 (enExample)
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
JP2006522692A5 (enExample)
JP2009075520A5 (enExample)
TW200745039A (en) Isotopically substituted pantoprazole
JP2001354766A5 (enExample)
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments
JP2003504349A5 (enExample)
DE602006001330D1 (de) Herstellung von 1-(Alkoxysilyl)ethyl-1,1,3,3-tetramethyldisiloxan
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
MY145368A (en) Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
WO2008072079A3 (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethylbenzamide
EA200602045A1 (ru) 2-замещённые пиримидины